Pediatric Drug Trial Priority Should Be Vincristine/Actinomysin-D, Cmte. Says
Executive Summary
A combination drug trial evaluating vincristine and actinomysin-D should be the top priority among off-patent drugs for a pediatric study, FDA's Pediatric Oncology Subcommittee recommended Oct. 9